<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="discussion" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="pmc-domain-id">1559</journal-id><journal-id journal-id-type="pmc-domain">viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12474342</article-id><article-id pub-id-type="pmcid-ver">PMC12474342.1</article-id><article-id pub-id-type="pmcaid">12474342</article-id><article-id pub-id-type="pmcaiid">12474342</article-id><article-id pub-id-type="pmid">41012684</article-id><article-id pub-id-type="doi">10.3390/v17091257</article-id><article-id pub-id-type="publisher-id">viruses-17-01257</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Commentary</subject></subj-group></article-categories><title-group><article-title>Mpox Epidemics: A Call to Restore Humanity&#8217;s Lost Herd Immunity to Orthopoxviruses</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Wayengera</surname><given-names initials="M">Misaki</given-names></name><xref rid="af1-viruses-17-01257" ref-type="aff">1</xref><xref rid="af2-viruses-17-01257" ref-type="aff">2</xref><xref rid="c1-viruses-17-01257" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6593-8727</contrib-id><name name-style="western"><surname>Kyobe-Bosa</surname><given-names initials="H">Henry</given-names></name><xref rid="af2-viruses-17-01257" ref-type="aff">2</xref><xref rid="af3-viruses-17-01257" ref-type="aff">3</xref><xref rid="af4-viruses-17-01257" ref-type="aff">4</xref><xref rid="c1-viruses-17-01257" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7154-2964</contrib-id><name name-style="western"><surname>Muttamba</surname><given-names initials="W">Winters</given-names></name><xref rid="af2-viruses-17-01257" ref-type="aff">2</xref><xref rid="af5-viruses-17-01257" ref-type="aff">5</xref><xref rid="c1-viruses-17-01257" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Olu</surname><given-names initials="OO">Olushayo Oluseun</given-names></name><xref rid="af6-viruses-17-01257" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gueye</surname><given-names initials="AS">Abdou Salam</given-names></name><xref rid="af6-viruses-17-01257" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ndembi</surname><given-names initials="N">Nicaise</given-names></name><xref rid="af7-viruses-17-01257" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kamara</surname><given-names initials="N">Neema</given-names></name><xref rid="af8-viruses-17-01257" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9008-7730</contrib-id><name name-style="western"><surname>Folayan</surname><given-names initials="MO">Morenike Oluwatoyin</given-names></name><xref rid="af9-viruses-17-01257" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kirenga</surname><given-names initials="B">Bruce</given-names></name><xref rid="af2-viruses-17-01257" ref-type="aff">2</xref><xref rid="af5-viruses-17-01257" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Luo</surname><given-names initials="S">Sitong</given-names></name><xref rid="af10-viruses-17-01257" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="Q">Qingyu</given-names></name><xref rid="af10-viruses-17-01257" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ihekweazu</surname><given-names initials="C">Chikwe</given-names></name><xref rid="af6-viruses-17-01257" ref-type="aff">6</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Schwartz</surname><given-names initials="DA">David A.</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Colebunders</surname><given-names initials="R">Robert</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Katoto</surname><given-names initials="P">Patrick</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-17-01257"><label>1</label>Department of Immunology &amp; Molecular Biology, College of Health Sciences, Makerere University, Kampala P.O. Box 7072, Uganda</aff><aff id="af2-viruses-17-01257"><label>2</label>Interdisciplinary Consortium for Epidemics Research, Kampala P.O. Box 189784, Uganda; <email>brucekirenga@yahoo.co.uk</email></aff><aff id="af3-viruses-17-01257"><label>3</label>Incident Management Team, Ministry of Health, Kampala P.O. Box 7272, Uganda</aff><aff id="af4-viruses-17-01257"><label>4</label>Uganda Peoples Defense Forces, Kampala P.O. Box 3798, Uganda</aff><aff id="af5-viruses-17-01257"><label>5</label>Makerere University Lung Institute, Kampala P.O. Box 7749, Uganda</aff><aff id="af6-viruses-17-01257"><label>6</label>World Health Organization Regional Office for Africa, Brazzaville P.O. Box 06, Republic of Congo<email>cihekweazu@who.int</email> (C.I.)</aff><aff id="af7-viruses-17-01257"><label>7</label>International Vaccine Institute, Kigali P.O. Box 3413, Rwanda; <email>nicaise.ndembi@ivi.int</email></aff><aff id="af8-viruses-17-01257"><label>8</label>Africa Centres for Disease Control and Prevention, Addis Ababa P.O. Box 3243, Ethiopia; <email>kamaran@africacdc.org</email></aff><aff id="af9-viruses-17-01257"><label>9</label>Department of Child Dental Health, Awolowo University, Ile-Ife 220005, Nigeria; <email>toyinukpong@yahoo.co.uk</email></aff><aff id="af10-viruses-17-01257"><label>10</label>Vanke School of Public Health, Tsinghua University, Beijing 100084, China; <email>sitongluo@mail.tsinghua.edu.cn</email> (S.L.); <email>liqingyu21@mails.tsinghua.edu.cn</email> (Q.L.)</aff><author-notes><corresp id="c1-viruses-17-01257"><label>*</label>Correspondence: <email>waymisaki@gmail.com</email> (M.W.); <email>hskyobe@gmail.com</email> (H.K.-B.); <email>wmuttamba@icer.org.ug</email> (W.M.)</corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>17</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">497677</issue-id><elocation-id>1257</elocation-id><history><date date-type="received"><day>19</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>04</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>05</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 18:25:14.327"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="viruses-17-01257.pdf"/><abstract><p>Global efforts to eradicate smallpox&#8212;an Orthopoxvirus infection&#8212;began in the mid-20th century, with the last naturally occurring case reported in 1977. This was achieved through global solidarity efforts that expanded the smallpox eradication vaccination program. Approximately 50 years following the cessation of mass smallpox vaccination and in the absence of access to a sustainable boosting program, the population immunologically na&#239;ve to Orthopoxviruses has increased significantly. With increasing global movements and travels, we argue that the emergence of two back-to-back yet distinct mpox epidemics in the 21st century is a sign of humanity&#8217;s lost herd immunity to Orthopoxviruses. This needs concerted efforts to restore.</p></abstract><kwd-group><kwd>mpox immunity</kwd><kwd>waning immunity</kwd><kwd>smallpox vaccination</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-17-01257"><title>1. Introduction</title><p><italic toggle="yes">Orthopoxviruses</italic> are a group of zoonotic, phylogenetically related, double-stranded DNA viruses. The genus <italic toggle="yes">Orthopoxvirus</italic> belongs to the family <italic toggle="yes">Poxviridae</italic>, under which there are several genera, including <italic toggle="yes">Parapoxvirus</italic>, <italic toggle="yes">Avipoxvirus</italic>, <italic toggle="yes">Capripoxvirus</italic>, <italic toggle="yes">Leporipoxvirus</italic>, <italic toggle="yes">Suipoxvirus</italic>, <italic toggle="yes">Molluscipoxvirus</italic>, and <italic toggle="yes">Yatapoxvirus</italic>. Historically, the most widely reported infection caused by an <italic toggle="yes">Orthopoxvirus</italic> is smallpox&#8212;a disease of humans from time immemorial. The global eradication program for smallpox started in the mid-20th century, with the World Health Organisation (WHO) proposing a global smallpox eradication program in 1959 [<xref rid="B1-viruses-17-01257" ref-type="bibr">1</xref>]. The timeline of events towards eradication is summarized in <xref rid="viruses-17-01257-f001" ref-type="fig">Figure 1</xref>.</p><p>Since 2022, humanity has faced two distinct but consecutive mpox (formerly monkeypox) outbreaks caused by the mpox virus (MPXV) [<xref rid="B2-viruses-17-01257" ref-type="bibr">2</xref>,<xref rid="B3-viruses-17-01257" ref-type="bibr">3</xref>]. The first outbreak (2022&#8211;2023) driven by Clade IIb spread, rapidly across Europe and North America. The current epidemic driven by Clade Ib began in August 2023 in South Kivu Province, Democratic Republic of Congo (DRC), and has since spread rapidly across East, Central, and Southern Africa [<xref rid="B4-viruses-17-01257" ref-type="bibr">4</xref>,<xref rid="B5-viruses-17-01257" ref-type="bibr">5</xref>,<xref rid="B6-viruses-17-01257" ref-type="bibr">6</xref>].</p><p>These two discrete but closely related epidemics of mpox have not only increased interest in the role of <italic toggle="yes">Orthopoxviruses</italic> in causing pandemics but also serve as an indication of humanity&#8217;s prevailing risk to and/or immunity against <italic toggle="yes">Orthopoxviruses</italic> [<xref rid="B7-viruses-17-01257" ref-type="bibr">7</xref>]. A growing school of thought attributes recent mpox outbreaks to waning <italic toggle="yes">Orthopoxvirus</italic> immunity, particularly among populations born after routine smallpox vaccination ceased [<xref rid="B8-viruses-17-01257" ref-type="bibr">8</xref>,<xref rid="B9-viruses-17-01257" ref-type="bibr">9</xref>]. It is estimated that up to 70% of the world&#8217;s population is no longer protected against smallpox and closely related <italic toggle="yes">Orthopoxviruses</italic> through cross-immunity [<xref rid="B10-viruses-17-01257" ref-type="bibr">10</xref>].</p><p>Vaccination has emerged as a medical countermeasure for responding to mpox; however, this is affected by the high cost and unavailability of enough doses of the common vaccines like Bavarian Nordic&#8217;s MVA-BN vaccine that was initially licensed for smallpox. Evidence shows smallpox vaccine-induced immunity has the potential to protect against other <italic toggle="yes">Orthopoxviridae</italic> viruses, including mpox [<xref rid="B11-viruses-17-01257" ref-type="bibr">11</xref>,<xref rid="B12-viruses-17-01257" ref-type="bibr">12</xref>,<xref rid="B13-viruses-17-01257" ref-type="bibr">13</xref>,<xref rid="B14-viruses-17-01257" ref-type="bibr">14</xref>] (<xref rid="viruses-17-01257-t001" ref-type="table">Table 1</xref>).</p></sec><sec id="sec2-viruses-17-01257"><title>2. A Case for a Global Vaccination Program to Restore Humanity&#8217;s Herd Immunity Against <italic toggle="yes">Orthopoxviruses</italic>: Strategies for Restoring <italic toggle="yes">Orthopoxviruses</italic> Herd Immunity</title><p>In the 1960s, the initial goal of the smallpox vaccination program was to vaccinate 80% of the population to achieve herd immunity [<xref rid="B19-viruses-17-01257" ref-type="bibr">19</xref>]. Given the dwindled herd immunity of most of the world&#8217;s population, we argue that the world needs to come together to see to it that this shield is restored rather than leaving the mandate to individual countries, some of which are too poor to afford the vaccines. Below we highlight the strategies for restoring <italic toggle="yes">Orthopoxvirus</italic> herd immunity.</p></sec><sec id="sec3-viruses-17-01257"><title>3. Targeted Smallpox Vaccination Strategies</title><p>The ring vaccination strategy has been credited for the smallpox eradication and involves creating a buffer of immunity around a case by vaccinating the contacts and ultimately preventing disease spread. The current mpox epidemic gives the world an opportunity to deploy the same strategy by utilizing proven smallpox vaccines. An epidemiology-based approach that hinges on robust case-finding strategies to identify mpox cases and identification and vaccination of high-risk individuals could potentially build herd immunity in a global population that lacks immunity against <italic toggle="yes">Orthopoxviruses</italic>. Such a strategy should be supported by dose-sparing approaches given the low stockpiles of these vaccines to ensure that high vaccination coverage [<xref rid="B20-viruses-17-01257" ref-type="bibr">20</xref>].</p></sec><sec id="sec4-viruses-17-01257"><title>4. Strategies to Ensure Global Equity and Access, Particularly in Endemic and Low-Income Regions</title><p>In the short term, there is a need for a clear demonstration of global solidarity to respond to the mpox outbreak. Such solidarity should acknowledge the failures witnessed during the COVID-19 pandemic, where low-resourced countries lacked sufficient vaccines for their populations. A globally coordinated framework to ensure mpox vaccines are available to endemic and low-income countries should be developed. Implementation should be informed by epidemiological need rather than financial capacity. A shift from centralized structures to structures that promote regional coordination and context-driven responses should be supported. This has been demonstrated on the African continent, where the Africa Centers for Disease Control and Prevention (Africa CDC) and WHO Regional Office for Africa (WHO/AFRO) have coordinated the mpox continental preparedness and response to achieve localized and equitable health responses [<xref rid="B21-viruses-17-01257" ref-type="bibr">21</xref>].</p></sec><sec id="sec5-viruses-17-01257"><title>5. Development of Newer, Cheaper, Safer and More Effective Vaccines: Safer, More Effective Vaccines with Broader Cross-Protection</title><p>In the medium to long term, mpox vaccine research and development should be scaled up, particularly in Africa. Vaccine developers should consider expanding their manufacturing footprint in Africa, where more than 70% of health technology requirements are imported. Countries should allocate sufficient research and development funding through several mechanisms such as multilateral financing schemes, assurance of demand to entice private sector investments, strengthened public&#8211;private partnerships, and deployment of policies that incentivize local investments in R&amp;D [<xref rid="B22-viruses-17-01257" ref-type="bibr">22</xref>]. African countries should be included in global vaccine clinical trials on an equal footing, as currently they contribute a paltry 3% of the trials [<xref rid="B23-viruses-17-01257" ref-type="bibr">23</xref>].</p></sec><sec id="sec6-viruses-17-01257"><title>6. Risk Communication and Community Engagement to Combat Vaccine Hesitancy and Misinformation</title><p>Additionally, investments in vaccine research and development should be supplemented by community engagement and participation in mpox vaccine deployment. This should be achieved through a well-developed and implemented Risk Communication and Community Engagement (RCCE) strategy. The RCCE strategy should be multidisciplinary and informed by the prevailing epidemiological, contextual, social, economic, cultural, and behavioral considerations. The RCCE strategy could leverage the available traditional and digital media channels [<xref rid="B24-viruses-17-01257" ref-type="bibr">24</xref>]. Countries should consider conducting research into social behaviors so as to understand human behaviors and inform the integration of risk communication and behavioral insights into the RCCE strategies [<xref rid="B24-viruses-17-01257" ref-type="bibr">24</xref>].</p></sec><sec id="sec7-viruses-17-01257"><title>7. Strengthen Integrated Surveillance Systems and Conduct Focused Research to Monitor and Track Progress of Herd Immunity</title><p>The ability of mpox vaccines to achieve individual and community-level (herd) immunity in various settings needs to be demonstrated and documented. In this regard, studies to assess the efficacy of the candidate mpox vaccines should be supported to provide data to support national rollout of mpox vaccination programs. With successful vaccine rollout, studies to measure the magnitude of any herd effects should become a priority, and this requires a high-quality mpox disease surveillance system. The systems should incorporate new technologies such as pathogen genomics, pathogen genetic sequence data sharing platforms, and advanced technologies like artificial intelligence.</p></sec><sec id="sec8-viruses-17-01257"><title>8. Financing</title><p>The above strategies need to be supported by sustainable financing mechanisms. In the wake of the current global upheaval, securing domestic financial resources to support vaccine development, research, and vaccination campaigns is critical. Establishing vaccination strategies and programs that enhance health security through self-sustaining financial mechanisms and reduced reliance on external donors is essential.</p></sec><sec sec-type="conclusions" id="sec9-viruses-17-01257"><title>9. Conclusions</title><p>Approximately 50 years since the smallpox vaccination program was halted following the eradication of smallpox, there has been no dedicated program for sustainable immune boosting. The majority of the world&#8217;s young people are at risk, with the Mpox outbreak being a warning sign of broader <italic toggle="yes">Orthopoxvirus</italic> vulnerability. The world urgently needs to restore humanity&#8217;s shield against her historically most notorious, indiscriminate, and highly fatal virus family. This is a call to action to rebuild population-level immunity through informed, equitable, and science-based approaches.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization: M.W., H.K.-B., B.K. and W.M.; Methodology: M.W. and H.K.-B.; Software: W.M.; Validation: O.O.O., A.S.G., N.N., N.K., M.O.F., B.K., S.L., Q.L. and C.I.; Resources: M.W., H.K.-B., B.K.; Data curation: H.K.-B. and W.M.; Writing&#8212;original draft preparation: M.W., H.K.-B. and W.M.; Writing&#8212;review and editing: B.K., O.O.O., A.S.G., N.N., N.K., M.O.F., S.L., Q.L. and C.I.; Visualization: W.M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-17-01257"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Hopkins</surname><given-names>D.R.</given-names></name></person-group><source>The Greatest Killer: Smallpox in History, with a New Introduction</source><publisher-name>University of Chicago Press</publisher-name><publisher-loc>Chicago, IL, USA</publisher-loc><year>1983</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://share.google/rDLPuIsJXi3JlUmNX" ext-link-type="uri">https://share.google/rDLPuIsJXi3JlUmNX</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-25">(accessed on 25 March 2025)</date-in-citation></element-citation></ref><ref id="B2-viruses-17-01257"><label>2</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organisation (WHO)</collab></person-group><article-title>WHO Director-General Declares the Ongoing Monkeypox Outbreak a Public Health Emergency of International Concern. Published 2022</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/europe/news/item/23-07-2022-who-director-general-declares-the-ongoing-monkeypox-outbreak-a-public-health-event-of-international-concern" ext-link-type="uri">https://www.who.int/europe/news/item/23-07-2022-who-director-general-declares-the-ongoing-monkeypox-outbreak-a-public-health-event-of-international-concern</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-26">(accessed on 26 March 2025)</date-in-citation></element-citation></ref><ref id="B3-viruses-17-01257"><label>3</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization (WHO)</collab></person-group><article-title>Mpox (Monkeypox)&#8212;Democratic Republic of the Congo. Published 2023</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON493" ext-link-type="uri">https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON493</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-26">(accessed on 26 March 2025)</date-in-citation></element-citation></ref><ref id="B4-viruses-17-01257"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masirika</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Udahemuka</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Schuele</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nieuwenhuijse</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Ndishimye</surname><given-names>P.</given-names></name><name name-style="western"><surname>Boter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mbiribindi</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Kacita</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gort&#225;zar</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Epidemiological and genomic evolution of the ongoing outbreak of clade Ib mpox virus in the eastern Democratic Republic of the Congo</article-title><source>Nat. Med.</source><year>2025</year><volume>31</volume><fpage>1459</fpage><lpage>1463</lpage><pub-id pub-id-type="doi">10.1038/s41591-025-03582-1</pub-id><pub-id pub-id-type="pmid">39933565</pub-id><pub-id pub-id-type="pmcid">PMC12092280</pub-id></element-citation></ref><ref id="B5-viruses-17-01257"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katoto</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Muttamba</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bahizire</surname><given-names>E.</given-names></name><name name-style="western"><surname>Malembaka</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Bosa</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Kazadi</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Lubambo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Siangoli</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Bakamutumaho</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wayengera</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Shifting transmission patterns of human mpox in South Kivu, DR Congo</article-title><source>Lancet Infect. Dis.</source><year>2024</year><volume>24</volume><fpage>e354</fpage><lpage>e355</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(24)00287-1</pub-id><pub-id pub-id-type="pmid">38703785</pub-id></element-citation></ref><ref id="B6-viruses-17-01257"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Penant</surname><given-names>G.</given-names></name><name name-style="western"><surname>Delerce</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boschi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wurtz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bedotto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Branger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brouqui</surname><given-names>P.</given-names></name><name name-style="western"><surname>Parola</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lagier</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Sequencing of monkeypox virus from infected patients reveals viral genomes with APOBEC3&#8212;Like editing, gene inactivation, and bacterial agents of skin superinfection</article-title><source>J. Med. Virol.</source><year>2023</year><volume>95</volume><fpage>e28799</fpage><pub-id pub-id-type="doi">10.1002/jmv.28799</pub-id><pub-id pub-id-type="pmid">37342884</pub-id></element-citation></ref><ref id="B7-viruses-17-01257"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luciani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lapidus</surname><given-names>N.</given-names></name><name name-style="western"><surname>Amroun</surname><given-names>A.</given-names></name><name name-style="western"><surname>Falchi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Souksakhone</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mayxay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dubot-P&#233;r&#232;s</surname><given-names>A.</given-names></name><name name-style="western"><surname>Villarroel</surname><given-names>P.M.S.</given-names></name><name name-style="western"><surname>Diarra</surname><given-names>I.</given-names></name><name name-style="western"><surname>Koita</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Orthopoxvirus Seroprevalence and Infection Susceptibility in France, Bolivia, Laos, and Mali</article-title><source>Emerg. Infect. Dis.</source><year>2022</year><volume>28</volume><fpage>2463</fpage><lpage>2471</lpage><pub-id pub-id-type="doi">10.3201/eid2812.221136</pub-id><pub-id pub-id-type="pmid">36343384</pub-id><pub-id pub-id-type="pmcid">PMC9707606</pub-id></element-citation></ref><ref id="B8-viruses-17-01257"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rimoin</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Mulembakani</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J.O.L.</given-names></name><name name-style="western"><surname>Kisalu</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Kinkela</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Blumberg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Thomassen</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Pike</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Fair</surname><given-names>J.N.</given-names></name><etal/></person-group><article-title>Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>16262</fpage><lpage>16267</lpage><pub-id pub-id-type="doi">10.1073/pnas.1005769107</pub-id><pub-id pub-id-type="pmid">20805472</pub-id><pub-id pub-id-type="pmcid">PMC2941342</pub-id></element-citation></ref><ref id="B9-viruses-17-01257"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taube</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Rest</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Lloyd-Smith</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Bansal</surname><given-names>S.</given-names></name></person-group><article-title>The global landscape of smallpox vaccination history and implications for current and future orthopoxvirus susceptibility: A modelling study</article-title><source>Lancet Infect. Dis.</source><year>2023</year><volume>23</volume><fpage>454</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00664-8</pub-id><pub-id pub-id-type="pmid">36455590</pub-id><pub-id pub-id-type="pmcid">PMC10040439</pub-id></element-citation></ref><ref id="B10-viruses-17-01257"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simpson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Heymann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Edmunds</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Elsgaard</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fine</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hochrein</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hoff</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Green</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ihekweazu</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Human monkeypox&#8212;After 40 years, an unintended consequence of smallpox eradication</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>5077</fpage><lpage>5081</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.04.062</pub-id><pub-id pub-id-type="pmid">32417140</pub-id><pub-id pub-id-type="pmcid">PMC9533855</pub-id></element-citation></ref><ref id="B11-viruses-17-01257"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sagy</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Zucker</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hammerman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Markovits</surname><given-names>H.</given-names></name><name name-style="western"><surname>Arieh</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Abu Ahmad</surname><given-names>W.</given-names></name><name name-style="western"><surname>Battat</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ramot</surname><given-names>N.</given-names></name><name name-style="western"><surname>Carmeli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mark-Amir</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Real-world effectiveness of a single dose of mpox vaccine in males</article-title><source>Nat. Med.</source><year>2023</year><volume>29</volume><fpage>748</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1038/s41591-023-02229-3</pub-id><pub-id pub-id-type="pmid">36720271</pub-id><pub-id pub-id-type="pmcid">PMC9930701</pub-id></element-citation></ref><ref id="B12-viruses-17-01257"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bertran</surname><given-names>M.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>N.</given-names></name><name name-style="western"><surname>Davison</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dugbazah</surname><given-names>B.</given-names></name><name name-style="western"><surname>Boateng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lunt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hardstaff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Green</surname><given-names>M.</given-names></name><name name-style="western"><surname>Blomquist</surname><given-names>P.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Effectiveness of one dose of MVA&#8212;BN smallpox vaccine against mpox in England using the case-coverage method: An observational study</article-title><source>Lancet Infect. Dis.</source><year>2023</year><volume>23</volume><fpage>828</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(23)00057-9</pub-id><pub-id pub-id-type="pmid">36924787</pub-id></element-citation></ref><ref id="B13-viruses-17-01257"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morino</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mine</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tomita</surname><given-names>N.</given-names></name><name name-style="western"><surname>Uemura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okumura</surname><given-names>N.</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Terada</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Mpox Neutralizing Antibody Response to LC16m8 Vaccine in Healthy Adults</article-title><source>NEJM Evid.</source><year>2024</year><volume>3</volume><fpage>EVIDoa2300290</fpage><pub-id pub-id-type="doi">10.1056/EVIDoa2300290</pub-id><pub-id pub-id-type="pmid">38411447</pub-id></element-citation></ref><ref id="B14-viruses-17-01257"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomita</surname><given-names>N.</given-names></name><name name-style="western"><surname>Terada-Hirashima</surname><given-names>J.</given-names></name><name name-style="western"><surname>Uemura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yano</surname><given-names>R.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Okumura</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sugiura</surname><given-names>W.</given-names></name><etal/></person-group><article-title>An open-label, non-randomized study investigating the safety and efficacy of smallpox vaccine, LC16, as post-exposure prophylaxis for mpox</article-title><source>Hum. Vaccines Immunother.</source><year>2023</year><volume>19</volume><fpage>2242219</fpage><pub-id pub-id-type="doi">10.1080/21645515.2023.2242219</pub-id><pub-id pub-id-type="pmcid">PMC10416734</pub-id><pub-id pub-id-type="pmid">37559375</pub-id></element-citation></ref><ref id="B15-viruses-17-01257"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matusali</surname><given-names>G.</given-names></name><name name-style="western"><surname>Petruccioli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cimini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Colavita</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bettini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tartaglia</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sbarra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Meschi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lapa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Francalancia</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Evaluation of Cross-Immunity to the Mpox Virus Due to Historic Smallpox Vaccination</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>1541</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11101541</pub-id><pub-id pub-id-type="pmid">37896943</pub-id><pub-id pub-id-type="pmcid">PMC10610801</pub-id></element-citation></ref><ref id="B16-viruses-17-01257"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karem</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Braden</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Nigam</surname><given-names>P.</given-names></name><name name-style="western"><surname>Crotty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Glidewell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>R.</given-names></name><name name-style="western"><surname>Amara</surname><given-names>R.</given-names></name><name name-style="western"><surname>Damon</surname><given-names>I.K.</given-names></name></person-group><article-title>Monkeypox-Induced Immunity and Failure of Childhood Smallpox Vaccination To Provide Complete Protection</article-title><source>Clin. Vaccine Immunol.</source><year>2007</year><volume>14</volume><fpage>1318</fpage><lpage>1327</lpage><pub-id pub-id-type="doi">10.1128/CVI.00148-07</pub-id><pub-id pub-id-type="pmid">17715329</pub-id><pub-id pub-id-type="pmcid">PMC2168110</pub-id></element-citation></ref><ref id="B17-viruses-17-01257"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hammarlund</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Amanna</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Strelow</surname><given-names>L.I.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Yoshihara</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hanifin</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Slifka</surname><given-names>M.K.</given-names></name></person-group><article-title>Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox</article-title><source>Nat. Med.</source><year>2005</year><volume>11</volume><fpage>1005</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.1038/nm1273</pub-id><pub-id pub-id-type="pmid">16086024</pub-id></element-citation></ref><ref id="B18-viruses-17-01257"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huhn</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Yorita</surname><given-names>K.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Sejvar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Likos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Damon</surname><given-names>I.K.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Kuehnert</surname><given-names>M.J.</given-names></name></person-group><article-title>Clinical Characteristics of Human Monkeypox, and Risk Factors for Severe Disease</article-title><source>Clin. Infect. Dis.</source><year>2005</year><volume>41</volume><fpage>1742</fpage><lpage>1751</lpage><pub-id pub-id-type="doi">10.1086/498115</pub-id><pub-id pub-id-type="pmid">16288398</pub-id></element-citation></ref><ref id="B19-viruses-17-01257"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Johnstone</surname><given-names>J.</given-names></name><name name-style="western"><surname>Loeb</surname><given-names>M.</given-names></name></person-group><article-title>Vaccine herd effect</article-title><source>Scand. J. Infect. Dis.</source><year>2011</year><volume>43</volume><fpage>683</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.3109/00365548.2011.582247</pub-id><pub-id pub-id-type="pmid">21604922</pub-id><pub-id pub-id-type="pmcid">PMC3171704</pub-id></element-citation></ref><ref id="B20-viruses-17-01257"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dimitrov</surname><given-names>D.</given-names></name><name name-style="western"><surname>Adamson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Matrajt</surname><given-names>L.</given-names></name></person-group><article-title>Evaluation of mpox vaccine dose-sparing strategies</article-title><source>PNAS Nexus</source><year>2023</year><volume>2</volume><fpage>pgad095</fpage><pub-id pub-id-type="doi">10.1093/pnasnexus/pgad095</pub-id><pub-id pub-id-type="pmid">37152676</pub-id><pub-id pub-id-type="pmcid">PMC10154907</pub-id></element-citation></ref><ref id="B21-viruses-17-01257"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ndembi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fol&#225;yan</surname><given-names>M.O.</given-names></name></person-group><article-title>A regional approach to addressing global health inequities</article-title><source>Lancet</source><year>2025</year><volume>405</volume><fpage>297</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(24)02638-2</pub-id><pub-id pub-id-type="pmid">39863360</pub-id></element-citation></ref><ref id="B22-viruses-17-01257"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ndembi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Karuna</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cowden</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cagigi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pilorget</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moodley</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ake</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vasan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Michael</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name></person-group><article-title>Accelerating vaccine development in Africa: Lessons from HIV research</article-title><source>Lancet</source><year>2025</year><volume>405</volume><fpage>1726</fpage><lpage>1728</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(25)00564-1</pub-id><pub-id pub-id-type="pmid">40222377</pub-id></element-citation></ref><ref id="B23-viruses-17-01257"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ndembi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mekonen</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Folayan</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Dereje</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kruger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fokam</surname><given-names>J.</given-names></name><name name-style="western"><surname>Temfack</surname><given-names>E.</given-names></name><name name-style="western"><surname>Raji</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nachega</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boum</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Strengthening and expanding capacities in clinical trials: Advancing pandemic prevention, preparedness and response in Africa</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>8662</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-53126-3</pub-id><pub-id pub-id-type="pmid">39375336</pub-id><pub-id pub-id-type="pmcid">PMC11458601</pub-id></element-citation></ref><ref id="B24-viruses-17-01257"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Njagi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nyikuri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ndembi</surname><given-names>N.</given-names></name></person-group><article-title>Integrating social behavioural insights in risk communication and community engagement approaches for better health outcomes in Africa</article-title><source>BMJ Glob. Health</source><year>2024</year><volume>9</volume><fpage>e015548</fpage><pub-id pub-id-type="doi">10.1136/bmjgh-2024-015548</pub-id><pub-id pub-id-type="pmid">39237297</pub-id><pub-id pub-id-type="pmcid">PMC11381717</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-17-01257-f001" orientation="portrait"><label>Figure 1</label><caption><p>Timeline of events towards global smallpox eradication.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-17-01257-g001.jpg"/></fig><table-wrap position="float" id="viruses-17-01257-t001" orientation="portrait"><object-id pub-id-type="pii">viruses-17-01257-t001_Table 1</object-id><label>Table 1</label><caption><p>Summary of studies demonstrating evidence of mpox and cross protection with smallpox and smallpox vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Title</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Authors</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Evidence</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample Size</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Evaluation of Cross-Immunity to the Mpox Virus Due to Historic Smallpox Vaccination</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Matusali G. et al. [<xref rid="B15-viruses-17-01257" ref-type="bibr">15</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1) Smallpox vaccinated: Anti-MPXV IgG was detected in 60 individuals (89.6%), while 40 (70.1%) of them had neutralising antibodies.<break/>(2) Unvaccinated: Anti-MPXV antibody levels were below the detection limit.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108 (71 smallpox vaccinated, 30 unvaccinated)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rimoin A.W. et al. [<xref rid="B8-viruses-17-01257" ref-type="bibr">8</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1) Vaccinated persons had a 5.2-fold lower risk of monkeypox than unvaccinated persons (0.78 vs. 4.05 per 10,000).<break/>(2) Smallpox vaccine has 80.7% (95% CI: 68.2&#8211;88.4) efficacy to prevent mpox and its incidence is inversely correlated with smallpox vaccination.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">760 laboratory-confirmed human monkeypox cases</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monkeypox-Induced Immunity and Failure of Childhood Smallpox Vaccination to provide complete protection</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Karem L. et al. [<xref rid="B16-viruses-17-01257" ref-type="bibr">16</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-existing immunity, assessed by high anti-Orthopoxvirus IgG levels and childhood smallpox vaccination, was associated (in a nonsignificant manner) with mild disease.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hammarlund E. et al. [<xref rid="B17-viruses-17-01257" ref-type="bibr">17</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
Demonstrated cross-protective antiviral immunity against West African monkeypox can potentially be maintained for decades after smallpox vaccination.
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical Characteristics of Human Monkeypox, and Risk Factors for Severe Disease</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Huhn G.D. et al [<xref rid="B18-viruses-17-01257" ref-type="bibr">18</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Previous smallpox vaccination was not associated with disease severity or hospitalization.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>